Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 42-year-old woman is evaluated in the intensive care unit on hospital day 3. She was initially admitted with septic shock secondary to a perforated appendix and underwent an emergency exploratory laparotomy. Her medical history is significant for generalized epilepsy, which has been well-controlled on oral valproic acid for the past 5 years. Upon admission, she was resuscitated with intravenous fluids and norepinephrine, and empiric therapy with intravenous meropenem and vancomycin was initiated. Her home dose of valproic acid was continued. Today, her hemodynamics have improved, and vasopressors have been discontinued. However, she experiences a 2-minute generalized tonic-clonic seizure that resolves spontaneously. Her vital signs are temperature 37.6°C (99.7°F), blood pressure 118/72 mm Hg, pulse 88/min, and respirations 16/min. Laboratory studies reveal a serum valproic acid level of 12 mcg/mL (therapeutic range: 50-100 mcg/mL), which is markedly decreased from a level of 65 mcg/mL drawn on admission. Renal and hepatic function panels are within normal limits. Based on the patient's current presentation, which of the following are the most appropriate immediate pharmacologic interventions? (Select all that apply)

  1. Discontinue meropenem and initiate intravenous piperacillin-tazobactamAnswer
  2. Administer an intravenous loading dose of levetiracetamAnswer
  3. C
    Administer an intravenous loading dose of valproic acid and increase the maintenance dose
  4. D
    Discontinue meropenem and initiate intravenous ciprofloxacin
  5. E
    Initiate maintenance therapy with oral ethosuximide

Answer

The most appropriate interventions are to discontinue meropenem and initiate intravenous piperacillin-tazobactam, and to administer an intravenous loading dose of levetiracetam.
The correct interventions directly address the severe pharmacokinetic interaction between meropenem and valproic acid. Carbapenems rapidly lower valproic acid serum concentrations by inhibiting the enzyme acylpeptide hydrolase, which normally cleaves the valproic acid-glucuronide conjugate back into active valproic acid. This leads to rapid renal excretion of the glucuronidated form. Consequently, meropenem must be discontinued. Because the patient has a perforated appendix, the alternative antibiotic must maintain robust Gram-negative and anaerobic coverage; piperacillin-tazobactam is an excellent choice. Furthermore, because the enzymatic inhibition takes days to reverse after carbapenem discontinuation, the patient is currently unprotected from seizures. Therefore, initiating an alternative, non-interacting broad-spectrum antiepileptic drug, such as levetiracetam, is necessary to provide immediate seizure prophylaxis.

Step-by-Step Solution

1
Identify the cause of the patient's breakthrough seizure.
The seizure is caused by a subtherapeutic valproic acid level (12 mcg/mL), which dropped significantly from admission.
Recognizing the etiology of the seizure dictates whether the patient needs adjustments to antiepileptic therapy or investigation of new neurologic insults.
2
Determine the mechanism behind the subtherapeutic valproic acid level.
The drop in valproic acid is due to a severe, well-documented pharmacokinetic drug-drug interaction with the carbapenem antibiotic (meropenem).
Carbapenems inhibit acylpeptide hydrolase, preventing the de-glucuronidation of valproic acid in the liver and erythrocytes, leading to rapid renal clearance of the drug. This interaction cannot be safely overcome by increasing the valproic acid dose.
3
Adjust the antimicrobial regimen.
Meropenem is discontinued, and piperacillin-tazobactam is initiated.
The interacting drug must be removed. However, the patient still requires broad-spectrum coverage, including potent anaerobic coverage, for the recently perforated appendix. Piperacillin-tazobactam provides this coverage without interacting with valproic acid.
4
Establish immediate seizure prophylaxis.
An intravenous loading dose of levetiracetam is administered.
Because it takes several days for the carbapenem to wash out and for valproic acid levels to recover, the patient remains at high risk for recurrent generalized tonic-clonic seizures. A non-interacting, broad-spectrum antiepileptic drug must be initiated immediately.

Key Concept

Carbapenem antibiotics (e.g., meropenem) cause a severe pharmacokinetic interaction with valproic acid, leading to rapid drug clearance and breakthrough seizures. Management requires discontinuing the carbapenem, ensuring alternative antimicrobial coverage, and initiating a non-interacting antiepileptic drug.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic